TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03653611

Intervention type: OTHER
Intervention: Clinical Staff Questionnaires
Description: Written or on-line questionnaires are provided to participating and consented staff personnel at two practice levels -- Non-Prescribing clinical (also known as support) staff and Prescribing (PR) clinical (also known as provider) staff.

Intervention type: OTHER
Intervention: Patient Opinion Surveys
Description: 200 Eligible participants will complete a one-time 5 to 10 minute CAPTURE opinion survey.

Intervention type: OTHER
Intervention: Modular online COPD Education
Description: Access to free, COPD on-line, continuing education is provided for all clinical staff at each practice. Each module will take 20 minutes or less. Aim 2 clinician participant access and completion of COPD education modules is assessed by clinician questionnaires and focus group item response over 12 months (between months 2 and 14 of Aim 2 timeline).

Intervention type: OTHER
Intervention: COPD in Primary Care/CAPTURE Introduction Focus Groups
Description: Two 45 to 60-minute focus group discussions occur at each Aim 2 practice. Focus groups are informed by practice demographics, practice assessment data, as well as patient opinion from CAPTURE surveys and past CAPTURE study. Focus group candidate themes and prompts are developed for non-prescribing clinical staff (NPR) and prescribing clinical staff (PR) and are presented at separate on-site focus group sessions to allow more detailed discussion of role responsibility in the context of daily practice workflow.
Study: NCT02115815

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo (sterile saline for human use from commercial source liquid) on Day 1.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV sF 20 mcg
Description: Participants will receive single dose of 20 mcg RSV sF by intramuscular injection on Day 1.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI7510 (20 mcg RSV sF)
Description: Participants will receive single dose of MEDI7510 containing 20 mcg RSV sF by intramuscular injection on Day 1.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV sF 50 mcg
Description: Participants will receive single dose of 50 mcg RSV sF by intramuscular injection on Day 1.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI7510 (50 mcg RSV sF)
Description: Participants will receive single dose of MEDI7510 containing 50 mcg RSV sF by intramuscular injection on Day 1.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV sF 80 mcg
Description: Participants will receive single dose of 80 mcg RSV sF by intramuscular injection on Day 1.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI7510 (80 mcg RSV sF)
Description: Participants will receive single dose of MEDI7510 containing 80 mcg RSV sF by intramuscular injection on Day 1.
Study: NCT01194557

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Rapid diagnostic test
Description: Diagnosis of malaria using rapid diagnostic test

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lumartem
Description: Presumptive treatment of malaria/fever
Study: NCT02114671

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Faldaprevir high dose
Description: capsules, oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: capsule, oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciprofloxacin
Description: tablets, oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Faldaprevir low dose
Description: capsules, oral
Study: NCT00533897

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abatacept
Description: Solution in pre-filled syringes, Subcutaneously, 125 mg, Weekly, (Short Term (3 periods - 12 weeks each; Long Term)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Solution in pre-filled syringes, Subcutaneously, 0 mg, Weekly, Period II 12 weeks (Short Term)
Study: NCT03423082

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F fluciclovine
Description: Each subject will receive one IV dose of 18F fluciclovine for PET scanning

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 18F fluciclovine PET
Description: Each subject will undergo one 18F fluciclovine PET scan on a hybrid PET/MRI scanner
Study: NCT01105884

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ceredak
Description: All the subjects in this group will be treated with Micro-porous Ceramic Wound Dressing
Study: NCT02028130

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LAA electrical isolation + occlusion
Description: LAA electrical isolation + Watchman device implantation to occlude LAA
Study: NCT02742142

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: water as placebo
Description: topical application of water as a placebo in the control arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: silver diammine fluoride
Description: topical application of the SDF solution onto tooth root surfaces
Study: NCT03684889

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SCRI-huCAR19v1
Description: 1:1 mixture of CD4:CD8 autologous T cells lentivirally transduced to express a second generation 4-1BB-ζ human CD19-specific CAR and Her2tG

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SCRI-huCAR19v2
Description: Mixture of CD4:CD8 autologous T cells lentivirally transduced to express a second generation 4-1BB-ζ human CD19-specific CAR and Her2tG
Study: NCT03068949

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: FluBlok
Description: FluBlok trivalent Influenza Vaccine .5 mL given Intramuscularly

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluzone
Description: Fluzone Quadrivalent Influenza Vaccine .5 mL given intramuscularly

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: FluCelVax
Description: FluCelVax Quadrivalent Influenza Vaccine .5 mL given intramuscularly

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluzone HD
Description: Fluzone HD Trivalent High Dose Influenza Vaccine .5 mL given intramuscularly
Study: NCT00785096

Intervention type: OTHER
Intervention: Questionnaire
Description: Questionnaire, complications, grading severity, visual analog scale

Intervention type: OTHER
Intervention: Questionnaire
Description: Questionnaire, complications, grading severity, visual analog scale

Intervention type: OTHER
Intervention: Questionnaire
Description: Questionnaire, complications, grading severity, visual analog scale
Study: NCT04502498

Intervention type: DIAGNOSTIC_TEST
Intervention: Lower limb duplex & doppler
Description: Lower limb duplex and doppler one week before radical cystectomy
Study: NCT01241682

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DC + CTX
Description: 3x 50x10e6 DC + cyclophosphamide
Study: NCT01319435

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Collection of biological samples
Description: Sparse blood samples (n=2 or 3 depending on weight) will be drawn on day 1 and day 5- 7 (or last day of treatment if the course is completed before day 7).~Monitoring of adverse events DNA for pharmacogenetics (scavenged clinical samples or buccal) CSF (if required clinically) Faeces
Study: NCT00637676

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: VATS, Talc-Pleurodesis, tunneled pleural drainage
Description: poudrage of 4 gr talc into the pleural cavity implantation of tunneled pleural catheter
Study: NCT05085834

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zinc Gluconate
Description: Two 45 mg capsules once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two placebo capsules once daily
Study: NCT03728478

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept
Description: Patients will receive etanercept subcutaneously at a dose of 0.8 mg/kg weekly (up to a maximum dose of 50 mg weekly).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Methotrexate will be administered subcutaneously, in a single weekly dose of 15 mg/m2 (max 20 mg).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intra-articular corticosteroid injections
Description: Triamcinolone hexacetonide and methylprednisolone acetate doses depend on the affected joint.
Study: NCT01416337

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1120212
Description: 2 mg single dose tablet on Day 1 of study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1120212B
Description: A single administration of a slow 1 minute IV push on Day 1.
Study: NCT03232567

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NasoVAX
Description: Single ascending dose study

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NasoVAX
Description: Single ascending dose study

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NasoVAX
Description: Single ascending dose study

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: NasoVAX
Description: Single ascending dose study
Study: NCT03592329

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress Reduction Training A
Description: twice weekly booster sessions and weekly instructor-led sessions for 8 weeks plus home practice sessions

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Stress Reduction Training A
Description: twice weekly booster sessions and weekly instructor-led sessions for 8 weeks plus home practice sessions
Study: NCT00637676

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: VATS, Talc-pleurodesis
Description: poudrage of 4 gr. talc into the pleural cavity no tunneled pleural catheter
Study: NCT03092440

Intervention type: OTHER
Intervention: serious game
Description: During three hours, each learner will play with the three different cases of the LabForGames Warning serious game.

Intervention type: OTHER
Intervention: serious game
Description: During three hours, each learner will play with the three different cases of the LabForGames Warning serious game.

Intervention type: OTHER
Intervention: serious game
Description: During three hours, each learner will play with the three different cases of the LabForGames Warning serious game.
Study: NCT03979651

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib plus hydroxychloroquine in patients with NRAS Melanoma (Dose 1)
Description: Standard dosing of trametinib at 2 milligrams (mg) by mouth once a day, with an escalation of hydroxychloroquine.~The escalation of hydroxychloroquine will be decided by a 3+3 design with the goal of estimating the Maximum Tolerated Dose (MTD) of trametinib plus hydroxychloroquine. A cycle of treatment will last 28 days. Patients will be evaluated weekly during the first cycle of treatment.~• Level -1 = Hydroxychloroquine 400 mg by mouth once a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib plus hydroxychloroquine in patients with NRAS Melanoma (Dose 2)
Description: Standard dosing of trametinib at 2 milligrams (mg) by mouth once a day, with an escalation of hydroxychloroquine.~The escalation of hydroxychloroquine will be decided by a 3+3 design with the goal of estimating the Maximum Tolerated Dose (MTD) of trametinib plus hydroxychloroquine. A cycle of treatment will last 28 days. Patients will be evaluated weekly during the first cycle of treatment.~• Level 1 (starting dose) = Hydroxychloroquine 800 mg by mouth once a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib plus hydroxychloroquine in patients with NRAS Melanoma (Dose 3)
Description: Standard dosing of trametinib at 2 milligrams (mg) by mouth once a day, with an escalation of hydroxychloroquine.~The escalation of hydroxychloroquine will be decided by a 3+3 design with the goal of estimating the Maximum Tolerated Dose (MTD) of trametinib plus hydroxychloroquine. A cycle of treatment will last 28 days. Patients will be evaluated weekly during the first cycle of treatment.~• Level 2 = Hydroxychloroquine 600 mg by mouth two times a day
Study: NCT03456817

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment Arm - high dose ATG
Description: Patients agreeing to high dose ATG will be treated with 2 mg/kg daily on days -4 to 0. On days -4, -3 \& -2, ATG will be infused after fludarabine \& busulfan infusion. ATG will be infused over a minimum of 6 hrs on day -4 \& over at least 4 hrs on days -3, -2, -1 \& 0. Dose is based on actual body wt, \& rounded to nearest vial-Thymoglobulin is supplied in 25 mg vials, except if rounding would result in \>5% difference from calculated dose. Foothills Medical Center Unit 57 standard practice followed for ATG infusion. ATG premeds include methylprednisolone, diphenhydramine, and an antipyretic. Meperidine 25-50 mg IVPB every 4 hours will be given as needed for rigors. MTX is given 15 mg/m2 IV on day +1 \& 10 mg/m2 on days +3, +6 \& +11 posttransplant. First dose of methotrexate is given on day +1, at least 24 hrs following end of infusion of stem cell product.

Intervention type: DRUG
Group type: OTHER
Intervention: Control Arm - standard of care
Description: The historical controls will have received and the concurrent controls will receive our standard GVHD prophylaxis, ie, ATG 4.5 mg/kg i.v. (0.5 mg/kg on day -2, 2.0 mg/kg on day -1 and 2.0 mg/kg on day 0), MTX (15 mg/m2 i.v. on day 1 and 10 mg/m2 i.v. on days 3, 6 and 11) and CSA (2.5 mg/kg twice a day i.v. starting from day -1, adjusting dose to target trough plasma CSA levels of 200-400 microg/L, switching to oral formulation before discharge from peritransplant hospitalization, targeting the trough plasma levels of 200-400 microg/L until day 56, and tapering to zero between day 56 and 84).
Study: NCT02934035

Intervention type: DRUG
Intervention: Antidepressant
Study: NCT03308487

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: vitamin D3 (1000 IU)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3 (2000 IU)
Study: NCT03114722

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Citrate 4%
Description: In patients randomised to the citrate arm, the PICC line will be locked with a total of 1.6ml of citrate 4% (0.8ml per lumen in a double-lumen PICC), between each use. Lines will also be flushed with 20ml of normal saline and locked with the locking agent twice a week, if the time elapsed between each use is more than one week. This is part of the standard local protocol. Patients will be followed for up to 6 months or until the catheter is removed, or until the study ends

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heparinised saline (10U/ml)
Description: In patients randomised to the heparinised saline arm, the PICC line will be locked with 10U/ml heparinised saline between each use. Lines will also be flushed with 20ml of normal saline and locked with the locking agent twice a week, if the time elapsed between each use is more than one week. This is part of the standard local protocol. Patients will be followed for up to 6 months or until the catheter is removed, or until the study ends
Study: NCT00735124

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin
Description: 1200 mg single dose gabapentin

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Injection of placebo/sham
Study: NCT04289129

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Myotonometric evaluation
Description: Vertically placed on the muscle, a probe (3 mm diameter) creates constant pre-excitations (0.18 N) and generates short-term (15 ms), low-force (0.4 N) mechanical stimulations.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Myotonometric evaluation
Description: Vertically placed on the muscle, a probe (3 mm diameter) creates constant pre-excitations (0.18 N) and generates short-term (15 ms), low-force (0.4 N) mechanical stimulations.
Study: NCT03102944

Intervention type: DIAGNOSTIC_TEST
Intervention: Minicare BNP
Description: no real intervention since only leftover materials are used from volunteers and samples are not tested on Minicare BNP IVD device near any volunteer.
Study: NCT00719576

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: autologous cultured chondrocytes on porcine collagen membrane
Description: Implantation via mini-arthrotomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Microfracture
Description: Microfracture performed by arthroscopic surgery
Study: NCT00678275

Intervention type: DRUG
Group type: OTHER
Intervention: ATG FRESENIUS (Anti-Lymphocyte-Globulin)
Description: conditioning regimen with ATG: ATG FRESENIUS dosing: 10mg/kg/day, (day -3, -2,-1) when randomised Arm A

Intervention type: DRUG
Group type: OTHER
Intervention: ATG FRESENIUS (Anti-Lymphocyte-Globulin)
Description: conditioning regimen WITHOUT ATG when randomised Arm B
Study: NCT01218932

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A
Description: Subjects in A group who receive regimen 1 of primaquine (PQ) on the first admission (visit 2) will receive regimen 2 of primaquine and chloroquine combination (PQ and CQ) on second admission (visit 3) after 1 week wash out period and will finish with regimen 3 of Chloroquine (CQ) on the third admission (visit 4) after 8 weeks wash out period.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: B
Description: Subjects in B group who receive regimen 1 of primaquine ( PQ) will receive regimen 2 of chloroquine (CQ) on second admission (visit 3) after 1 week wash out period and regimen 3 of primaquine and chloroquine combination (PQ and CQ)on third admission( visit 4) with 8 week wash out period in between.
Study: NCT02592603

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endocuff-assisted Colonoscopy
Description: Colonic examination with Endocuff-assisted Colonoscopy
Study: NCT03554005

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG Interferon Alfa-2b
Description: Participants receive PEG interferon alfa-2b administered by SC injection, in doses ranging from 0.75 mcg/kg OW up to 7.5 mcg/kg OW, for up to 40 weeks of treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG Interferon Alfa-2b
Description: Participants receive PEG interferon alfa-2b administered by SC injection, in doses ranging from 0.75 mcg/kg OW up to 7.5 mcg/kg OW, for up to 40 weeks of treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG Interferon Alfa-2b
Description: Participants receive PEG interferon alfa-2b administered by SC injection, in doses ranging from 0.75 mcg/kg OW up to 7.5 mcg/kg OW, for up to 40 weeks of treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG Interferon Alfa-2b
Description: Participants receive PEG interferon alfa-2b administered by SC injection, in doses ranging from 0.75 mcg/kg OW up to 7.5 mcg/kg OW, for up to 40 weeks of treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG Interferon Alfa-2b
Description: Participants receive PEG interferon alfa-2b administered by SC injection, in doses ranging from 0.75 mcg/kg OW up to 7.5 mcg/kg OW, for up to 40 weeks of treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG Interferon Alfa-2b
Description: Participants receive PEG interferon alfa-2b administered by SC injection, in doses ranging from 0.75 mcg/kg OW up to 7.5 mcg/kg OW, for up to 40 weeks of treatment.
Study: NCT02899403

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rapid Visual Information Processing (RVIP) test
Description: Rapid Visual Information Processing is a measure of sustained attention.
Study: NCT01150032

Intervention type: OTHER
Intervention: Bone quality complementary exams
Description: realisation of following exams to evaluate fracture risk in osteopenic women:~* hip and wrist Dual energy X-ray Absorptiometry (DXA)~* wrist and shin High-Resolution peripheral Quantitative Computed-Tomography(HR-pQCT)~* hip Quantitative Computed Tomography (QCT)~* High Resolution Digital X-Ray of calcaneum using BMA(tm) system~* low-dose stereoradiography using EOS(tm) system (only for a sub-group of 60 voluntary subjects)
Study: NCT02423694

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: electro-acupuncture
Description: 8 acupoint: Guanyuan, Zigong (bilateral), Tianshu(bilateral), Sanyinjiao(bilateral), Hegu(bilateral), Taichong(bilateral), Baihui, Yintang.~Every patient is supposed to have 36 times acupuncture treatment. 30 minutes per time. Baihui, Yintang, Zigong (bilateral), Tianshu (bilateral) are applied with electro-acupuncture device with dilatational wave, current frequency: 10/50Hz, intensity: 0.5\~1.0 mA

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: escitalopram oxalate tablets
Description: escitalopram oxalate tablet, once a day, 0.5 hour after breakfast, oral taken, 10mg, for 12 weeks
Study: NCT04605666

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19-CAR-T2 Cells
Description: CD19-CAR-T2 T cells will be infused over 10-15 minutes on Day 0.
Study: NCT03554005

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Participants receive 500 to 1000 mg of acetaminophen orally 30 minutes prior to PEG interferon alfa-2b administration, and continue acetaminophen 500 to 1000 mg after administration every 4 to 6 hours as needed. The total daily dose of acetaminophen should not exceed 3000 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Participants receive 500 to 1000 mg of acetaminophen orally 30 minutes prior to PEG interferon alfa-2b administration, and continue acetaminophen 500 to 1000 mg after administration every 4 to 6 hours as needed. The total daily dose of acetaminophen should not exceed 3000 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Participants receive 500 to 1000 mg of acetaminophen orally 30 minutes prior to PEG interferon alfa-2b administration, and continue acetaminophen 500 to 1000 mg after administration every 4 to 6 hours as needed. The total daily dose of acetaminophen should not exceed 3000 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Participants receive 500 to 1000 mg of acetaminophen orally 30 minutes prior to PEG interferon alfa-2b administration, and continue acetaminophen 500 to 1000 mg after administration every 4 to 6 hours as needed. The total daily dose of acetaminophen should not exceed 3000 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Participants receive 500 to 1000 mg of acetaminophen orally 30 minutes prior to PEG interferon alfa-2b administration, and continue acetaminophen 500 to 1000 mg after administration every 4 to 6 hours as needed. The total daily dose of acetaminophen should not exceed 3000 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Participants receive 500 to 1000 mg of acetaminophen orally 30 minutes prior to PEG interferon alfa-2b administration, and continue acetaminophen 500 to 1000 mg after administration every 4 to 6 hours as needed. The total daily dose of acetaminophen should not exceed 3000 mg.
Study: NCT04913714

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 3-month radio intervention on infant vaccination
Description: Radio intervention comprising 10-minute drama, 10-minute discussion of the drama by trained health extension workers and 30-minute phone-in from listeners